Skip to main
SRZN

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen is a promising bio-technology company with strong potential for success in the treatment of retinal diseases. Their product candidates, including SZN-8141 and SZN-413, have shown positive preclinical results in stimulating Wnt signaling, promoting retinal vessel regrowth, and reducing vascular leakage. With continued progress in their clinical development and validation from their strategic partner Boehringer Ingelheim, we view Surrozen as an attractive investment opportunity. However, potential risks to consider are unexpected toxicities or failures in clinical trials and the need for substantial financing.

Bears say

Surrozen is a clinical-stage biotech company developing novel therapeutics in severe eye disease and other organs with a focus on Wnt signaling pathway, a mediator of tissue repair. While their recent milestone and financial updates are promising, there are still many important questions on how their therapies will be differentiated and incorporated into treatment plans. Additionally, their cash reserves may not be enough to support the initial studies for their lead product candidates, and their success in preclinical studies may not guarantee success in clinical trials.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.